MacroGenics, Inc.
Deimmunized Serum-Binding Domains and Their Use in Extending Serum Half-Life

Last updated:

Abstract:

The present invention is directed to a polypeptide (for example, an antigen-binding molecule) that comprises a polypeptide portion of a deimmunized serum-binding protein capable of binding to said serum protein. The presence of the serum-binding protein extends the serum half-life of the polypeptide, relative to the serum half-life of the polypeptide if lacking the polypeptide portion of the deimmunized serum-binding protein. The invention also pertains to methods and uses that employ such molecules.

Status:
Application
Type:

Utility

Filling date:

28 Jun 2019

Issue date:

26 Mar 2020